Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study
Orlowski R, et al.
Blood
February 2026
Authors and Affiliates
Robert Orlowski (The University of Texas MD Anderson Cancer Center, United States) Meletios
Dimopoulos (Department of Clinical Therapeutics, National and Kapodistrian University of Athens,
Athens, Greece, Department of Medicine, Korea University, Seoul, Republic of Korea, Greece) Xavier
Leleu (Hopital La Miletrie, France) Thierry Facon (Centre Hospitalier Universitaire (CHU) Lille,
Service des Maladies du Sang, University of Lille, France) Tadao Ishida (Japanese Red Cross Medical
Center, Japan) Roman Hajek (University Hospital Ostrava and Faculty of Medicine, University of
Ostrava, Czech Republic) Ivan Spicka (Charles University and General Faculty Hospital, Prague,
Czech Republic) Joanna Romejko-Jarosinska (Marie Sklodowska-Curie National Research Institute of
Oncology, Poland) Vladimir Vorobyev (S.P. Botkin Hospital, Russian Federation) Britta Besemer
(University Hospital of Tuebingen, Germany) Sevgi Kalayoglu Besisik (Istanbul University Istanbul
Medical Faculty, Turkey) Pawel Robak (Medical University of Łódź, Łódź, Poland, Poland) Tomas
Jelínek (University Hospital Ostrava, Czech Republic) Hartmut Goldschmidt (Universitätsklinikum
Heidelberg, Med. Klinik V, GMMG-Studygroup, Germany) Thomas Martin (University of California, San
Francisco, United States) Mohamad Mohty (Hôpital Saint-Antoine, INSERM UMRs 938, and Université
Sorbonne, France) Sandrine Macé (Sanofi, France) Ercem Kodas (Sanofi, France) Christina Tekle
(Sanofi, United States) Andrea Shafer (Sanofi, United States) Philippe Moreau (Hematology,
University Hospital Hôtel-Dieu, France)